株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

欧州の非小細胞肺癌治療市場の機会:2010〜2020年

Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020

発行 Pharmaion 商品コード 351612
出版日 ページ情報 英文 122 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
欧州の非小細胞肺癌治療市場の機会:2010〜2020年 Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020
出版日: 2016年02月04日 ページ情報: 英文 122 Pages
概要

欧州では癌による死亡総数の約20%が肺癌です。2014年には5年生存率が男性で11.2%、女性で13.9%と、肺癌は欧州の癌による死亡の主な原因となっています。その多くが非小細胞肺癌であり、これは2020年まで続くと予測されます。非小細胞肺癌の罹患率が上昇する中、同疾患の治療に対する需要は今後5年間も着実に拡大するとみられています。

当レポートでは、欧州の非小細胞肺癌治療市場について調査し、市場の規模とシェア、2020年までの予測、疾患別、地域別動向、法規制環境、新興の機会と競合動向、および参入企業のプロファイルなどをまとめています。

第1章 非小細胞肺癌治療概要

第2章 調査方法

第3章 アナリストの見解

第4章 世界の非小細胞肺癌治療市場概要

第5章 欧州の肺癌疫学

第6章 欧州の非小細胞肺癌治療市場概要

第7章 欧州の非小細胞肺癌治療市場見通し

  • 市場規模と予測
  • 市場シェアと予測
    • 標的疾患別
    • タイプ別
    • 地域別
    • 企業別

第8章 欧州の地域別動向

第9章 セグメント別見通し

  • 化学療法
  • 手術
  • 放射線療法
  • 標的療法

第10章 市場動向

  • 促進因子
  • 課題

第11章 市場動向と発展

  • 免疫療法における新たな治療法の開発
  • 映像支援胸部手術
  • 光線力学的療法
  • レーザー治療
  • バイオマーカー

第12章 政策と法規制環境

第13章 製品ロードマップ

第14章 競合環境

  • 企業プロファイル
    • Roche Holding AG
    • Eli Lilly and Company Limited
    • Boehringer Ingelheim GmbH
    • Pfizer AG
    • AstraZeneca
    • Celgene International Sarl
    • Bristol-Myers Squibb
    • Merck Sharp & Dohme Limited
    • Novartis AG
    • Teva Pharmachemie

第15章 戦略的提言

図表

目次
Product Code: P013

In Europe, lung cancer accounts for around 20% of the total deaths due to cancer. With a 5-year survival rate of 11.2% for men and 13.9% for women in 2014, lung cancer is the leading cause of cancer related deaths in Europe. Majority of the lung cancer patients in Europe were found to be suffering from Non-Small Cell Lung Cancer (NSCLC) in 2014, and the trend is anticipated to continue through 2020. Hence, with increasing prevalence of NSCLC among European citizens, demand for NSCLC treatment is forecast to grow at a robust pace over the next five years.

“Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020” report studies the market size and share of various segments and sub-segments of the non- small cell lung cancer treatments market in the Europe during the period 2010 - 2020. In the study, the market has been categorized into four broader segments that include Chemotherapy, Surgery, Radiotherapy & Target Therapy.

The market dynamics section of the report elaborates the factors that are driving the market as well as the challenges inhibiting growth. The research study also includes insights of the key market trends, a detailed analysis of the changing competitive landscape, and revenue forecasts for each segment and sub-segment.

All this information is provided to assist the established market players and new entrants in taking their strategic decisions, thereby aiding them in strengthening their market position in a highly competitive non-small cell lung cancer treatments market in Europe.

“Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020” report elaborates the following aspects of non-small cell lung cancer treatments market in Europe:

  • Europe Non-Small Cell Lung Cancer Treatments Market Size, Share & Forecast
  • Segmental Analysis - By Target Disease, By Type, By Region, By Company
  • Policy & Regulatory Landscape
  • Changing Market Trends & Emerging Opportunities
  • Competitive Landscape & Strategic Recommendations

Why You Should Buy This Report?

  • To identify the on-going trends and anticipated growth in the next five years
  • To gain competitive knowledge of leading market players
  • To avail 10% customization in the report without any extra charges and get the research data or trends added in the report as per the buyer's specific needs

Key Questions This Study Will Answer

  • What would be the segmental and regional growth trends in the Europe non-small cell lung cancer treatments market in the coming years?
  • What are the most important growth drivers and opportunities in the market?
  • Which therapy is preferred the most?
  • What strategies should market competitors employ to gain share in mature segments of the Europe non-small cell lung cancer treatments market?
  • What are the competitor profiles in this market and how do they compete for market share?

Report Methodology

The information contained in this report is based upon both primary and secondary sources. Primary research included interviewswith NSCLC drug manufacturers, healthcare providers and industry experts.Secondary research included an exhaustive search of relevant publications likecompany annual reports, financial reports and proprietary databases.

Table of Contents

1. Non-Small Cell Lung Cancer Treatment Overview

2. Research Methodology

3. Analyst View

4. Global Non-Small Cell Lung Cancer Treatment Market Overview

5. Europe Lung Cancer Epidemiology

6. Europe Non-Small Cell Lung Cancer Treatment Market Overview

7. Europe Non-Small Cell Lung Cancer Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Targeted Disease (Squamous & Non-squamous)
    • 7.2.2. By Type (Surgery, Radiotherapy, Chemotherapy & Target Therapy)
    • 7.2.3. By Region (Germany, UK, Italy, France, Spain & RoE)
    • 7.2.4. By Company

8. Europe Non-Small Cell Lung Cancer Treatment Regional Market Outlook

  • 8.1. Germany Non-Small Cell Lung Cancer Treatment Market Analysis
    • 8.1.1. Market Size & Forecast
      • 8.1.1.1. By Value
    • 8.1.2. Market Share & Forecast
      • 8.1.2.1. By Type (Surgery, Radiotherapy, Chemotherapy& Target Therapy)
  • 8.2. Italy Non-Small Cell Lung Cancer Treatment Market Analysis
    • 8.2.1. Market Size & Forecast
      • 8.2.1.1. By Value
    • 8.2.2. Market Share & Forecast
      • 8.2.2.1. By Type (Surgery, Radiotherapy, Chemotherapy& Target Therapy)
  • 8.3. Spain Non-Small Cell Lung Cancer Treatment Market Analysis
    • 8.3.1. Market Size & Forecast
      • 8.3.1.1. By Value
    • 8.3.2. Market Share & Forecast
      • 8.3.2.1. By Type (Surgery, Radiotherapy, Chemotherapy& Target Therapy)
  • 8.4. UK Non-Small Cell Lung Cancer Treatment Market Analysis
    • 8.4.1. Market Size & Forecast
      • 8.4.1.1. By Value
    • 8.4.2. Market Share & Forecast
      • 8.4.2.1. By Type (Surgery, Radiotherapy, Chemotherapy& Target Therapy)
  • 8.5. France Non-Small Cell Lung Cancer Treatment Market Analysis
    • 8.5.1. Market Size & Forecast
      • 8.5.1.1. By Value
    • 8.5.2. Market Share & Forecast
      • 8.5.2.1. By Type (Surgery, Radiotherapy, Chemotherapy& Target Therapy)

9. Europe Non-Small Cell Lung Cancer Treatment Segmental Market Outlook

  • 9.1. Europe NSCLC Chemotherapy Market Outlook
    • 9.1.1. Market Size & Forecast
      • 9.1.1.1. By Value
    • 9.1.2. Market Share & Forecast
      • 9.1.2.1. By Type (First Line Therapy, Maintenance Therapy, Second Line Therapy, Third Line Therapy & Adjuvant Therapy)
  • 9.2. Europe NSCLC Surgery Market Outlook
    • 9.2.1. Market Size & Forecast
      • 9.2.1.1. By Value
    • 9.2.2. Market Share & Forecast
      • 9.2.2.1. By Type (Lobectomy, Sleeve Resection, Segmentectomy, Pneumonectomy & Others)
  • 9.3. Europe NSCLC Radiotherapy Market Outlook
    • 9.3.1. Market Size & Forecast
      • 9.3.1.1. By Value
    • 9.3.2. Market Share & Forecast
      • 9.3.2.1. By Type (External Beam Radiation therapy, Internal Beam Radiation Therapy & Systemic Radiation Therapy)
  • 9.4. Europe NSCLC Target Therapy Market Outlook
    • 9.4.1. Market Size & Forecast
      • 9.4.1.1. By Value
    • 9.4.2. Market Share & Forecast
      • 9.4.2.1. By Type (Monoclonal Antibodies (MABs) + Gene Therapy & Others)

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends and Developments

  • 11.1. Development of New Therapeutics in Immunotherapy
  • 11.2. Video Assisted Thoracic Surgery
  • 11.3. Photodynamic Therapy (PDT)
  • 11.4. Laser Therapy
  • 11.5. Biomarkers

12. Policy and Regulatory Landscape

  • 13. Europe NSCLC Product Roadmap
  • 14. Competitive Landscape
  • 14.1. Company Profiles
    • 14.1.1. Roche Holding AG
    • 14.1.2. Eli Lilly and Company Limited
    • 14.1.3. Boehringer Ingelheim GmbH
    • 14.1.4. Pfizer AG
    • 14.1.5. AstraZeneca
    • 14.1.6. Celgene International Sárl
    • 14.1.7. Bristol-Myers Squibb
    • 14.1.8. Merck Sharp & Dohme Limited
    • 14.1.9. Novartis AG
    • 14.1.10. Teva Pharmachemie

15. Strategic Recommendations

List of Figures

  • Figure 1: Europe Lung Cancer Incidences, By Gender, 2012& 2015E
  • Figure 2: Europe Number of Deaths due to Lung Cancer, By Gender, 2012 & 2015E
  • Figure 3: Europe Lung Cancer Prevalence, By Country, 2012
  • Figure 4: Europe Non-Small Cell Lung Cancer Treatment Market Size, By Value, 2010-2020F (USD Million)
  • Figure 5: Europe Non-Small Cell Lung Cancer Treatment Market, By Target Disease, By Value, 2010-2020F
  • Figure 6: Europe Non-Small Cell Lung Cancer Treatment Market Share, By Type, By Value, 2010-2020F
  • Figure 7: Europe Non-Small Cell Lung Cancer Treatment Market Share, By Region, By Value, 2010-2020F
  • Figure 8: Europe Non-Small Cell Lung Cancer Treatment Market Share, By Company, By Value, 2010-2020F
  • Figure 9: Germany Non-Small Cell Lung Cancer Treatment Market Size, By Value, 2010-2020F (USD Million)
  • Figure 10: Germany Non-Small Cell Lung Cancer Treatment Market Share, By Type, By Value, 2010-2020F
  • Figure 11: France Non-Small Cell Lung Cancer Treatment Market Size, By Value, 2010-2020F (USD Million)
  • Figure 12: France Non-Small Cell Lung Cancer Treatment Market Share, By Type, By Value, 2010-2020F
  • Figure 13: Spain Non-Small Cell Lung Cancer Treatment Market Size, By Value, 2010-2020F (USD Million)
  • Figure 14: Spain Non-Small Cell Lung Cancer Treatment Market Share, By Type, By Value, 2010-2020F
  • Figure 15: Italy Non-Small Cell Lung Cancer Treatment Market Size, By Value, 2010-2020F (USD Million)
  • Figure 16: Italy Non-Small Cell Lung Cancer Treatment Market Share, By Type, By Value, 2010-2020F
  • Figure 17: United Kingdom Non-Small Cell Lung Cancer Treatment Market Size, By Value, 2010-2020F (USD Million)
  • Figure 18: United Kingdom Non-Small Cell Lung Cancer Treatment Market Share, By Type, By Value, 2010-2020F
  • Figure 19: Europe Non-Small Cell Lung Cancer Chemotherapy Market Size, By Value, 2010-2020
  • Figure 20: Europe Non-Small Cell Lung Cancer Chemotherapy Market Share, By Type, By Value, 2010-2020
  • Figure 21: Europe Non-Small Cell Lung Cancer Surgery Market Size, By Value, 2010-2020
  • Figure 22: Europe Non-Small Cell Lung Cancer Surgery Market Share, By Type, By Value, 2010-2020
  • Figure 23: Europe Non-Small Cell Lung Cancer Radiotherapy Market Size, By Value (USD Million), 2010-2020
  • Figure 24: Europe Non-Small Cell Lung Cancer Radiotherapy Market Share, By Type, By Value, 2010-2020
  • Figure 25: Europe Non-Small Cell Lung Cancer Target Therapy Market Size, By Value, 2010-2020 (USD Million)
  • Figure 26: Europe Non-Small Cell Lung Cancer Target Therapy Market Share, By Type, By Value, 2014 & 2020F

List of Tables

  • Table 1: Non-Small Cell Lung Cancer Treatment Algorithm, By Stage
  • Table 2: Europe Lung Cancer Incidence and Prevalence Rate, By Country, 2012 (%)
  • Table 3: Europe NSCLC Patient Population Undergoing Drug Therapy, 2012
  • Table 4: Average Lifetime Cost Per Patient of NSCLC Treatment in Europe, By Target Disease, 2014 (USD)
  • Table 5: Europe Average Lifetime NSCLC Treatment Cost Per Patient, By Country, 2014 (USD)
  • Table 6: Europe Prevalence of Tobacco Use, By Age Group, By Country, 2015 & 2020E (%)
  • Table 7: Germany Proportion of Non-Small Cell Lung Cancer Patients Undergoing Different Treatment Therapies, By Stage (%)
  • Table 8: Proportion of NSCLC Patients Diagnosed in England, By Stage, 2014 (%)
  • Table 9: Proportion of Patients with Recurrent Lung Cancer in England, By Stage, 2014
  • Table 10: Individual NSCLC Patient Treatment Cost (USD) in England, By Therapy Type, 2014
  • Table 11: Europe Non-Small Cell Lung Cancer Chemotherapeutic Agents
  • Table 12: Europe Marketed Partial List of Target Therapy Drug
  • Table 13: List of Therapeutic Vaccines under Clinical Trial in European Union in 2015
  • Table 14: List of Immunotherapy Drug in European Union in 2015
  • Table 15: List of National Regulatory Authority in Top 5 European Union Countries for Authorization of Drugs
  • Table 16: List of Pipeline Drugs under Clinical Trial Phase 3 for NSCLC in European Union, 2015
  • Table 17: List of Marketed Targeted Therapy Drugs for NSCLC in European Union, 2015
Back to Top